GBA1
GBA1 (glucosylceramidase beta 1, also known as GBA or GLUC) is a lysosomal membrane enzyme that hydrolyses glucosylceramide into ceramide and glucose. It has a central role in the degradation of complex lipids and the turnover of cellular membranes. Browse Assay Genie's current range of GBA1 research reagents below, or read on for the biology behind the target.
GBA1 is a glucosylceramidase that acts within the lysosomal compartment. It catalyses the hydrolysis of glucosylceramides (GlcCers) into free ceramides and glucose, cleaving the beta-glucosidic linkage of glycosylceramide, an intermediate in glycolipid metabolism. In this way it plays a central role in the degradation of complex lipids and the turnover of cellular membranes. Through the production of ceramides, it also participates in the PKC-activated salvage pathway of ceramide formation.
The enzyme has additional activities beyond simple hydrolysis. GBA1 catalyses the glucosylation of cholesterol by transglucosylation, transferring glucose from GlcCer to cholesterol, and GlcCer containing mono-unsaturated fatty acids are preferred glucose donors over saturated equivalents. Under specific conditions it may catalyse the reverse reaction, moving glucose from cholesteryl 3-beta-D-glucoside to ceramide, and it can also hydrolyse cholesteryl 3-beta-D-glucoside to glucose and cholesterol. It hydrolyses galactosylceramides, and transfers galactose between GalCers and cholesterol in vitro, but with lower activity than with GlcCers. Xylosylceramide is a poor substrate for hydrolysis but a good xylose donor for transxylosylation, and the enzyme can also metabolise plant glycosyl phytosterols such as glucosylstigmasterol.
The human GBA1 gene encodes a lysosomal membrane protein that belongs to the glycosyl hydrolase 30 family; HGNC places it in the glycoside hydrolase family and the glucosylceramidases group. Mutations in the gene cause Gaucher disease, a lysosomal storage disease characterised by accumulation of glucocerebrosides. A related pseudogene lies downstream on chromosome 1, and alternative splicing gives multiple transcript variants. Earlier names include glucosidase, beta, acid, and the symbol GBA, now replaced by GBA1. The mouse ortholog is Gba1.
Mutations in GBA1 cause Gaucher disease, so the enzyme is a central subject in studies of this lysosomal storage disorder.
GBA1 hydrolyses glucosylceramide to ceramide and glucose, making it a key enzyme for studying glycolipid turnover and the ceramide salvage pathway.
Loss of GBA1 activity leads to accumulation of glucocerebrosides, providing a model for how lysosomal enzyme defects affect lipid homeostasis.
GBA1 catalyses transglucosylation between glucosylceramide and cholesterol, and hydrolyses cholesteryl glucoside, supporting work on sterol glycosylation.
GBA1 is a lysosomal glucosylceramidase that hydrolyses glucosylceramides into ceramide and glucose, contributing to complex lipid degradation and membrane turnover. It can also transfer glucose between glucosylceramide and cholesterol, and hydrolyse cholesteryl glucoside and galactosylceramides.
Yes. GBA and GLUC are earlier symbols for the gene now named GBA1 (glucosylceramidase beta 1). Previous names include glucosylceramidase and glucosidase, beta, acid. The UniProt entry calls the protein lysosomal acid glucosylceramidase. Alternative splicing yields multiple transcript variants.
Mutations in the GBA1 gene cause Gaucher disease, a lysosomal storage disease marked by accumulation of glucocerebrosides. The mouse counterpart is Gba1, so check the datasheet of any product for its validated reactivity.
Other glucosylceramidase and glycoside hydrolase family members involved in glycolipid metabolism.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P04062; product specifications from Assay Genie datasheets.